CTLA4-Ig: A novel immunosuppressive agent

Expert Opinion on Investigational Drugs

Volumn 9, Issue 9, 2000, Pages 2147-2157

  Najafian, N ^a   Sayegh, M H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Autoimmunity; Costimulation; CTLA4 Ig; Immunosuppression; Transplantation

Indexed keywords

AZATHIOPRINE; B7 ANTIGEN; CD28 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CLONAL ANERGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PSORIASIS; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0033865436     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.9.2147     Document Type: Article

References (82)

1. Renal transplantation
2. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide
3. Mechanisms of action and overview of OKT3
4. The mechanism of action of cyclosporin A and FK506
5. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 Kd S6 protein kinases
6. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta
7. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells
8. The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection
9. Chronic allograft failure: The clinical problem
10. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases
11. The role of T-cell costimulatory activation pathways in transplant rejection
12. The role of the CD28 receptor during T cell responses to antigen
13. The B7 and CD28 receptor families
14. CTLA-4 is a second receptor for the B cell activation antigen B7
15. CTLA-4 ligation blocks CD28-dependent T cell activation
16. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
17. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
18. CTLA-4 can function as a negative regulator of T cell activation
19. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
20. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice
21. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
22. The role of CD80, CD86 and CTLA4 in alloimmune responses and the induction of long-term allograft survival
23. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
24. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
25. T cell clonal anergy
26. CD28 costimulation prevents cell death during primary T cell activation
27. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule
28. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system
29. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
30. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4
31. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
32. CD28/B7 system of T cell costimulation
33. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
34. CD80 costimulation is essential for the induction of airway eosinophilia
35. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
36. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig
37. Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig
38. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice
39. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice
40. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
41. Treatment of murine lupus with CTLA4Ig
42. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2
43. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis
44. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis
45. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
46. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis
47. Suppression of murine allergic contact dermatitis by CTLA4-Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand
48. The role of costimulation in airway inflammation
49. B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens
50. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model
51. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury
52. Prevention and treatment of Factor VIII inhibitors in murine hemophilia A
53. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis
54. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD
55. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
56. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts
57. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules
58. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo
59. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
60. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism
61. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients
62. Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig
63. The time course of CTLAIg effect on cardiac allograft rejection
64. CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat
65. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis
66. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection
67. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection
68. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: Effects of cyclosporine and donor antigen
69. The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival
70. Blockade of multiple costimulatory receptors induces hyporesponsiveness: Inhibition of CD2 plus CD28 pathways
71. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment
72. Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig
73. Synergism of CTLA4-IG and anti-CD4 monoclonal antibody treatment in a rat kidney transplant model
74. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival
75. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
76. Importance of the CD28/B7 costimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation
77. CTLA4-Ig treatment prolongs rat orthotopic liver grafts survival
78. Donor-specific transfusions enhance the immunosuppressive effects of single-dose cyclosporine A and CTLA4-Ig but do not result in long-term graft acceptance in a histoincompatible model of rat lung allograft rejection
79. Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig
80. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
81. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation
82. Transplantation of anergic histoincompatible bone marrow allografts